Johnson & Johnson MedTech has received FDA clearance for MONARCH QUEST, the latest advancement in MONARCH navigation technology, featuring AI-powered algorithms and a verified OEC Open interface with the GE HealthCare OEC 3D mobile CBCT Imaging System.
The MONARCH Platform, which the company is calling the first robotically assisted bronchoscopy system to market, provides minimally invasive access to and visualization of airways to help clinicians biopsy suspicious lung nodules.
“Our goal with the MONARCH Platform is to change the treatment paradigm for diseases such as lung cancer, where significant unmet needs still remain,” said Aleksandra Popovic, President, MONARCH, Johnson & Johnson MedTech. “MONARCH QUEST demonstrates our commitment to delivering meaningful innovation that helps clinicians advance the standard of care for their patients.”
MONARCH QUEST builds on the platform’s reach and precision with its scope-in-sheath design and continuous vision for the physician. The software also integrates enhanced navigation in the MONARCH Platform with intraprocedural 3D imaging data with the potential to improve accuracy in targeting lung nodules.
MONARCH QUEST AI-powered navigation now uses the full-stack NVIDIA accelerated computing platform, based on NVIDIA RTX, increasing the platform’s real-time computational power by 260%, and allowing the system to run complex algorithms to enhance accuracy and confidence while navigating the lung.
MONARCH QUEST also adds more AI capabilities for future software releases as the MONARCH Platform grows to meet the demand for robotically assisted bronchoscopy procedures.
